Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy

Background and Aim The serial serologic changes of hepatitis D virus (HDV) infection among chronic hepatitis B virus (HBV) infected patients who received oral nucleotide/nucleoside analogues are elusive. Methods Serum anti‐HDV and HDV RNA among chronic hepatitis B (CHB) patients were tested at the t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2020-11, Vol.35 (11), p.1886-1892
Main Authors: Jang, Tyng‐Yuan, Wei, Yu‐Ju, Hsu, Cheng‐Ting, Hsu, Po‐Yao, Liu, Ta‐Wei, Lin, Yi‐Hung, Liang, Po‐Cheng, Hsieh, Meng‐Hsuan, Ko, Yu‐Min, Tsai, Yi‐Shan, Chen, Kuan‐Yu, Lin, Ching‐Chih, Tsai, Pei‐Chien, Wang, Shu‐Chi, Huang, Ching‐I, Yeh, Ming‐Lun, Lin, Zu‐Yau, Chen, Shinn‐Cherng, Chuang, Wan‐Long, Huang, Jee‐Fu, Dai, Chia‐Yen, Huang, Chung‐Feng, Yu, Ming‐Lung
Format: Article
Language:English
Subjects:
Administration, Oral
Age Factors
Antibodies, Viral - blood
Chronic infection
Coinfection - diagnosis
Coinfection - virology
Female
Follow-Up Studies
Hepatitis B
Hepatitis B e antigen
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - virology
hepatitis D
Hepatitis D - diagnosis
Hepatitis D - virology
Hepatitis delta virus
Hepatitis Delta Virus - genetics
Hepatitis Delta Virus - immunology
Humans
Interferon
Male
Middle Aged
nucleos(t)ides analogues
Nucleoside analogs
Nucleosides - administration & dosage
Nucleosides - analogs & derivatives
Nucleotide analogs
prevalence
Ribonucleic acid
RNA
RNA, Viral - blood
Serologic Tests
spontaneous clearance
Taiwan
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim The serial serologic changes of hepatitis D virus (HDV) infection among chronic hepatitis B virus (HBV) infected patients who received oral nucleotide/nucleoside analogues are elusive. Methods Serum anti‐HDV and HDV RNA among chronic hepatitis B (CHB) patients were tested at the time of initiating anti‐HBV therapy and subsequently during the follow‐up period. Results The seropositive rate of anti‐HDV and HDV RNA among 2850 CHB patients, was 2.7% and 0.9%, respectively. Factors associated with anti‐HDV seropositivity were platelet counts (odds ratio [OR]/95% confidence intervals [CI]: 0.995/0.992–0.999; P = 0.006), HBV DNA levels (OR/CI: 0.81/0.70–0.94; P = 0.005), and hepatitis B e‐antigen (HBeAg) seropositivity (OR/CI: 0.22/0.05–0.95; P = 0.04). The only factor associated with HDV RNA positivity among anti‐HDV seropositive patients was age (OR/CI: 0.95/0.90–1.00; P = 0.03). The spontaneous clearance rate of serum anti‐HDV antibody was 3.0 per 100 person‐years with a median follow‐up period of 3.5 years (range 2–12 years), whereas the seroclearance rate of HDV RNA was 4.3 per 100 person‐years among anti‐HDV seropositive patients after a median follow‐up period of 6.0 years (range 2–11 years). A baseline anti‐HDV titer 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.15061